{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T07:12:21Z","timestamp":1648969941685},"reference-count":0,"publisher":"Akademiai Kiado Zrt.","issue":"44","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orvosi Hetilap"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:p> Polycythaemia vera (PV), a condition characterized by blood hyperviscosity due to the expansion of the erythrocyte mass is the most common entity among all Philadelphia chromosome-negative myeloproliferative neoplasms. Arterial and venous thrombotic events are leading determinants of morbidity and mortality but impairment of quality of life due to vasomotor symptoms (erythromelalgia, pruritus) and disease-associated symptoms (tiredness, fatigue, pruritus, night sweats, vision problems, headache, concentration loss, abdominal discomfort, early satiety, fever, weight loss) are also present. The review of polycythaemia vera is actual as the updated WHO 2016 classification of myeloid neoplasms has changed the diagnostic criteria and a new second-line treatment option \u2013 JAK1\/JAK2 inhibitor ruxolitinib \u2013 has been approved for patients who had an inadequate response to or are intolerant of hydroxyurea, which represents a breakthrough in the treatment of this patient population. Orv. Hetil., 2016, 157(44), 1743\u20131751. <\/jats:p>","DOI":"10.1556\/650.2016.30583","type":"journal-article","created":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T05:50:50Z","timestamp":1477806650000},"page":"1743-1751","source":"Crossref","is-referenced-by-count":0,"title":["\u00dajdons\u00e1gok, aktualit\u00e1sok a polycythaemia vera                     diagnosztik\u00e1j\u00e1ban \u00e9s kezel\u00e9s\u00e9ben"],"prefix":"10.1556","volume":"157","author":[{"given":"Imelda","family":"Marton","sequence":"first","affiliation":[{"name":"II. Belgy\u00f3gy\u00e1szati Klinika \u00e9s Kardiol\u00f3giai K\u00f6zpont,                     Haematol\u00f3giai Oszt\u00e1ly, Szegedi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Szeged, Semmelweis u. 8., 6725"},{"name":"Transzfuziol\u00f3giai Tansz\u00e9k, Szegedi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Szeged"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zs\u00f3fia","family":"Simon","sequence":"additional","affiliation":[{"name":"Hematol\u00f3giai Tansz\u00e9k, Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Debrecen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zita","family":"Borb\u00e9nyi","sequence":"additional","affiliation":[{"name":"II. Belgy\u00f3gy\u00e1szati Klinika \u00e9s Kardiol\u00f3giai K\u00f6zpont,                     Haematol\u00f3giai Oszt\u00e1ly, Szegedi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Szeged, Semmelweis u. 8., 6725"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","container-title":["Orvosi Hetilap"],"original-title":[],"language":"hu","link":[{"URL":"https:\/\/www.akademiai.com\/doi\/pdf\/10.1556\/650.2016.30583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T19:29:29Z","timestamp":1550604569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akademiai.com\/doi\/10.1556\/650.2016.30583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":0,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1556\/650.2016.30583"],"URL":"https:\/\/doi.org\/10.1556\/650.2016.30583","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}